Fibrosis Lessens After Metabolic Surgery

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 11, 2024

Primary Completion Date

May 31, 2029

Study Completion Date

December 31, 2029

Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)Non-Alcoholic Fatty Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis (MASH)Liver FibrosisObesity
Interventions
PROCEDURE

Metabolic surgery

Patients receive either RYGB or SG. The surgical risk, differential impact of each procedure on body weight and other obesity-related diseases, presence of other medical and mental problems, patient's behavioral factors (e.g., postoperative compliance, active smoking), medications, and goals will be considered when the patient and local medical team make a shared decision about the most appropriate surgical procedure

DRUG

Incretin-Based Therapy

Three incretin-based medications that have been approved for treatment of obesity including liraglutide, semaglutide, or tirzepatide will be used in the nonsurgical group. Any of these 3 medications (in the injection or oral from) based on availability in each country, access, and clinical indications can be used. If possible, patients will be placed on high-dose tirzepatide (Mounjaro or Zepbound 15 mg once weekly injection) or high-dose semaglutide (Wegovy 2.4 mg once weekly injection or Ozempic 2 mg once weekly injection). Other acceptable, less preferrable, options: liraglutide (Saxenda or Victoza), semaglutide tablet (Rybelsus), or lower dose of tirzepatide and semaglutide injections.

Trial Locations (22)

44195

RECRUITING

Cleveland Clinic, Cleveland

46202

NOT_YET_RECRUITING

Indiana University, Indianapolis

55905

NOT_YET_RECRUITING

Mayo Clinic, Rochester

85006

NOT_YET_RECRUITING

Banner Health Center, Phoenix

Unknown

RECRUITING

Hospital Alemão Oswaldo Cruz, São Paulo

NOT_YET_RECRUITING

McGill University, Montreal

NOT_YET_RECRUITING

Turku University Hospital, Turku

NOT_YET_RECRUITING

Sri Aurobindo Institute of Medical Sciences, Indore

NOT_YET_RECRUITING

The Digestive Health Institute, Mumbai

NOT_YET_RECRUITING

University College Dublin, Dublin

NOT_YET_RECRUITING

Università Cattolica del Sacro Cuore, Milan

NOT_YET_RECRUITING

Sapienza Università di Roma, Roma

NOT_YET_RECRUITING

Kuwait University, Kuwait City

NOT_YET_RECRUITING

Instituto Nacional de Ciencias Médicas y Nutrición Salvador, Mexico City

NOT_YET_RECRUITING

Hospital Clínic Barcelona, Barcelona

NOT_YET_RECRUITING

Linköping University, Linköping

NOT_YET_RECRUITING

Örebro University, Örebro

NOT_YET_RECRUITING

Clarunis Universitäres, Basel

NOT_YET_RECRUITING

Hôpitaux universitaires de Genève, Geneva

NOT_YET_RECRUITING

Nuffield Health Bristol Hospital, Bristol

NOT_YET_RECRUITING

King's College Hospital, London

NOT_YET_RECRUITING

Queen Mary University, London

All Listed Sponsors
collaborator

Sobia Laique, MD

UNKNOWN

lead

Ali Aminian

OTHER

NCT06374875 - Fibrosis Lessens After Metabolic Surgery | Biotech Hunter | Biotech Hunter